160003-66-7 | 4-Iodo-3-nitrobenzamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$15.00	$10.00
5mg	98%	in stock	$18.00	$12.00
10mg	98%	in stock	$22.00	$15.00
25mg	98%	in stock	$26.00	$18.00
100mg	98%	in stock	$39.00	$27.00
250mg	98%	in stock	$48.00	$33.00
1g	98%	in stock	$58.00	$40.00
5g	98%	in stock	$100.00	$70.00
25g	98%	in stock	$349.00	$244.00

Description

• Catalog Number: AA82231
• Chemical Name: 4-Iodo-3-nitrobenzamide
• CAS Number: 160003-66-7
• Molecular Formula: C7H5IN2O3
• Molecular Weight: 292.0307
• MDL Number: MFCD11110639
• SMILES: [O-][N+](=O)c1cc(ccc1I)C(=O)N

Computed Properties

• Complexity: 228
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 13
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 1
• XLogP3: 1.3

Literature

• Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.

  Cell metabolism 20140603

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.

  Gynecologic oncology 20120901

• Neoadjuvant treatments for triple-negative breast cancer (TNBC).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120801

• Current and emerging targeted therapies for metastatic breast cancer.

  Cancer 20120615

• Dissecting the heterogeneity of triple-negative breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120520

• Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.

  Journal of the National Cancer Institute 20120502

• Nickel-catalysed aromatic Finkelstein reaction of aryl and heteroaryl bromides.

  Chemical communications (Cambridge, England) 20120425

• [PARP inhibitors and breast cancer: update and perspectives].

  Bulletin du cancer 20120401

• Drug candidates derailed in case of mistaken identity.

  Nature 20120328

• Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

• Present status and problems on molecular targeted therapy of cancer.

  Cancer research and treatment : official journal of Korean Cancer Association 20120301

• Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120115

• Basal breast cancer: a complex and deadly molecular subtype.

  Current molecular medicine 20120101

• Ovarian cancer: opportunity for targeted therapy.

  Journal of oncology 20120101

• BRCAness profile of sporadic ovarian cancer predicts disease recurrence.

  PloS one 20120101

• Molecular basis of triple negative breast cancer and implications for therapy.

  International journal of breast cancer 20120101

• Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.

  International journal of breast cancer 20120101

• Major clinical research advances in gynecologic cancer in 2011.

  Journal of gynecologic oncology 20120101

• Advances in using PARP inhibitors to treat cancer.

  BMC medicine 20120101

• Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

  Journal of oncology 20120101

• Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene.

  PloS one 20120101

• Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.

  Journal of oncology 20120101

• The first European interdisciplinary ewing sarcoma research summit.

  Frontiers in oncology 20120101

• Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.

  Journal of the National Cancer Institute 20111207

• The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

  Therapeutic advances in medical oncology 20111101

• Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

  Cancer science 20111001

• PARP inhibitors--current status and the walk towards early breast cancer.

  Breast (Edinburgh, Scotland) 20111001

• DNA-damaging therapies emerging as possible triple-negative breast cancer therapies.

  Oncology (Williston Park, N.Y.) 20111001

• PARP inhibitors: its role in treatment of cancer.

  Chinese journal of cancer 20110701

• Novel agents and future directions for refractory breast cancer.

  Seminars in oncology 20110601

• Iniparib in metastatic triple-negative breast cancer.

  The New England journal of medicine 20110505

• Few positives for triple-negative breast cancer.

  Journal of the National Cancer Institute 20110406

• Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

  Anticancer research 20110401

• Triple negative breast cancer: unmet medical needs.

  Breast cancer research and treatment 20110201

• Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

  The New England journal of medicine 20110120

• PARP and cancer--if it's broke, don't fix it.

  The New England journal of medicine 20110120

• PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

  Acta clinica Belgica 20110101

• Promising molecular targeted therapies in breast cancer.

  Indian journal of pharmacology 20110101

• Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

  Cancer management and research 20110101

• Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.

  BMC pharmacology 20110101

• Drug therapy for hereditary cancers.

  Hereditary cancer in clinical practice 20110101

• Management options in triple-negative breast cancer.

  Breast cancer : basic and clinical research 20110101

• Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

  Breast cancer research : BCR 20110101

• Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?

  Ecancermedicalscience 20110101

• Triple-negative breast cancer: adjuvant therapeutic options.

  Chemotherapy research and practice 20110101

• [PARP inhibitors to treat triple negative breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101201

• Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.

  IDrugs : the investigational drugs journal 20100901

• Small-molecule PARP modulators--current status and future therapeutic potential.

  Current opinion in drug discovery & development 20100901

• Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.

  Journal of the National Cancer Institute 20100804

• Treatment options for patients with triple-negative breast cancer.

  Journal of hematology & oncology 20100101

• Directed therapy of subtypes of triple-negative breast cancer.

  The oncologist 20100101

• Enzymatic mechanism of the tumoricidal action of 4-iodo-3-nitrobenzamide.

  Molecular medicine reports 20090101

• Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease.

  Biochemical pharmacology 20020201

• Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture.

  Biochemical pharmacology 19950825